Engraftment syndrome (ES) is a non-infectious febrile complication of hematopoietic cell transplantation (HCT), with diagnostic challenges, particularly in the allogeneic setting.
The increasing use of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis highlights the need for a re-examination of ES in this contemporary context.
